top of page

Pre-clinical Data to be Presented at The IASLC 16th World Conference On Lung Cancer

Dublin, Ireland, September 8, 2015 – Inflection Biosciences Ltd, a private company developing highly innovative treatments for cancer, today announced that data on IBL-202, a dual mechanism PIM/PI3 kinase inhibitor and IBL-301, a PIM/PI3K/mTOR inhibitor, will be highlighted in a poster presentation at the International Association of Lung Cancer (IASLC) 16th World Conference on Lung Cancer being held in Denver, CO from September 6-9, 2015.

The pre-clinical data was generated through a collaboration between Inflection Biosciences and Trinity College Dublin, led by Dr. Kathy Gately, Clinical Lecturer Thoracic Oncology Research at the Institute of Molecular Medicine, St. James’s Hospital Dublin.

The details for the poster presentation are as follows:

Date & Time: 9:30 am - 4:30 pm Tuesday 8th September, 2015

Poster Title: Targeting PIM kinase in NSCLC

Presenter: Dr. Martin Barr (for Dr. Kathy Gately)

Abstract Number: 933 (P2.04-057)

Session Title: Biology, Pathology, and Molecular Testing

Location: Poster Exhibit Hall (B+C)

The full abstract can be viewed here.

About PIM/PI3 kinase inhibitors

The PI3K/AKT pathway is commonly activated in human cancer. Multiple small-molecule inhibitors have been developed to target PI3K/mTOR or AKT kinases, but the efficacy of these drugs is compromised by the stimulation of compensatory signaling pathways. One example of such compensatory pathways is that driven by PIM kinases, which produce parallel oncogenic signals to AKT and mTOR and share several downstream molecular targets. Therefore, combined inhibition of such activities in a single molecule might have the potential to achieve better clinical efficacy and prevent/suppress resistance in comparison with classical PI3K/AKT/mTOR inhibitors.

About Inflection Biosciences

Inflection Biosciences Ltd, based in Dublin and London, is developing small molecule therapeutics for the treatment of cancer. The company's pipeline of highly innovative cancer treatments was licensed from the Spanish National Cancer Research Centre (CNIO). The pipeline comprises IBL-202 (PIM/PI3K inhibitor) and IBL-301 (PIM/PI3K/mTOR inhibitor), selected from a series of unique dual mechanism kinase inhibitors and the IBL-100 series (highly selective pan-PIM kinase inhibitors), currently in pre-clinical stages of development. Data generated to date suggests potential application in a range of haematological malignancies and treatment resistant solid tumours. Inflection Biosciences was named ‘Start-up Company of the Year’ at the 2014 Irish Pharma Awards. For more information please visit


bottom of page